Treatment of Chronic Hepatitis C Infection: Update of the Recommendations from Scientific Leader’s Meeting-28th July 2011-Tehran, IR Iran

AUTHORS

Seyed Moayed Alavian 1 , * , Kamran B Lankarani 2 , Seyed Hossein Aalaei-Andabili 1 , Ali Pouryasin 3 , Nasser Daryani 4 , Mohsen Nasiritoosi 4 , Reza Malekzadeh 5 , Mohammad Reza Zali 6 , Mino Mohraz 7

1 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran

2 Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran

3 Islamic Azad University, Arsanjan Branch, Basic Science Faculty, Biology Department, Arsanjan, IR Iran

4 Tehran University of Medical Sciences, Tehran, IR Iran

5 Digestive Disease Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, IR Iran

6 Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran,, IR Iran

7 Iranian Research Center for HIV/AIDS (IRCHA), Tehran University of Medical Sciences, Tehran, IR Iran

How to Cite: Alavian S M, B Lankarani K, Aalaei-Andabili S H, Pouryasin A, Daryani N, et al. Treatment of Chronic Hepatitis C Infection: Update of the Recommendations from Scientific Leader’s Meeting-28th July 2011-Tehran, IR Iran, Hepat Mon. 2011 ; 11(9):e93018.

ARTICLE INFORMATION

Hepatitis Monthly: 11 (9); e93018
Published Online: September 30, 2011
Article Type: Review Article
Received: May 06, 2019
Accepted: September 30, 2011

Crossmark

CHEKING

READ FULL TEXT
Abstract

Complete name and affiliation of collaborators are listed at the end of this article as an Appendix ( page: 711 ). 

Hepatitis C remains as an important health problem worldwide. Hepatitis C treatment, especially among patients infected with HCV genotype 1 who are considered difficult to treat, is a high priority for health policy-makers. PegInterferon alfa instead of Interferon and ribavirin combination therapy has been accepted as the standard treatment regimen for hepatitis C patients; however, only 50% of patients infected with HCV genotype 1 achieve a sustained virological response. Published data from various clinical trials of protease inhibitors suggest that new therapeutic regimens may increase the chances of a successful response in patients infected with HCV genotype 1. Triple therapy that includes boceprevir has been shown to result in high rates of sustained virological response in both naive and experienced patients with HCV genotype 1 infection. In this review, we have summarized the results obtained with this new regimen and have attempted to provide a guideline for the treatment of patients in Iran, with emphasis on cost and the occurrence of adverse events.

Implication for health policy/practice/research/medical education: 
Proper treatment of hepatitis C to control the burden of disease is essential in the society. Nowadays with the new methods of therapy the hope of eradication is more than before. This study is recommended to internal medicine and infectious disease specialists, gastroenterologists, general practitioners, virologists and health policy makers.

Please cite this paper as:
Alavian SM, Lankarani KB, Aalaei-Andabili SH, Pouryasin A, Ebrahimi Daryani N, Nassiri Toosi M, et al. Treatment of Chronic Hepatitis C Infection: Updated of the Recommendations from Scientific Leaders' Meeting-28th July 2011-Tehran, IR Iran. Hepat Mon. 2011; 11(9):703-13. DOI: 10.5812/kowsar.1735143X.769

Keywords

Hepatitis C Therapy Public health Iran

© 2011, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Fulltext

References

  • 1.

    The references are available in the PDF file.

  • COMMENTS

    LEAVE A COMMENT HERE: